These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 17674980)
1. Radiotherapy adapted to spatial and temporal variability in tumor hypoxia. Søvik A; Malinen E; Skogmo HK; Bentzen SM; Bruland OS; Olsen DR Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1496-504. PubMed ID: 17674980 [TBL] [Abstract][Full Text] [Related]
2. Predicting the effect of temporal variations in PO2 on tumor radiosensitivity. Kirkpatrick JP; Cárdenas-Navia LI; Dewhirst MW Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):822-33. PubMed ID: 15183486 [TBL] [Abstract][Full Text] [Related]
3. Adapting radiotherapy to hypoxic tumours. Malinen E; Søvik A; Hristov D; Bruland ØS; Olsen DR Phys Med Biol; 2006 Oct; 51(19):4903-21. PubMed ID: 16985278 [TBL] [Abstract][Full Text] [Related]
4. Dosimetric comparison between 2-dimensional radiation therapy and intensity modulated radiation therapy in treatment of advanced T-stage nasopharyngeal carcinoma: to treat less or more in the planning organ-at-risk volume of the brainstem and spinal cord. Chau RM; Teo PM; Kam MK; Leung SF; Cheung KY; Chan AT Med Dosim; 2007; 32(4):263-70. PubMed ID: 17980826 [TBL] [Abstract][Full Text] [Related]
5. Dynamic contrast enhanced magnetic resonance imaging of bladder cancer and implications for biological image-adapted radiotherapy. Røe K; Muren LP; Rørvik J; Olsen DR; Dahl O; Bakke A; Malinen E Acta Oncol; 2008; 47(7):1257-64. PubMed ID: 18618299 [TBL] [Abstract][Full Text] [Related]
6. Dosimetric comparison between 3DCRT and IMRT using different multileaf collimators in the treatment of brain tumors. Ding M; Newman F; Chen C; Stuhr K; Gaspar LE Med Dosim; 2009; 34(1):1-8. PubMed ID: 19181248 [TBL] [Abstract][Full Text] [Related]
7. The impact of different dose-response parameters on biologically optimized IMRT in breast cancer. Ferreira BC; Mavroidis P; Adamus-Górka M; Svensson R; Lind BK Phys Med Biol; 2008 May; 53(10):2733-52. PubMed ID: 18448874 [TBL] [Abstract][Full Text] [Related]
8. A split-organ delineation approach for dose optimisation for intensity-modulated radiotherapy for advanced T-stage nasopharyngeal carcinoma. Chau RM; Leung SF; Kam MK; Cheung KY; Kwan WH; Yu KH; Chiu SK; Chan AT Clin Oncol (R Coll Radiol); 2008 Mar; 20(2):134-41. PubMed ID: 18031999 [TBL] [Abstract][Full Text] [Related]
9. Normal tissue complication probability: does simultaneous integrated boost intensity-modulated radiotherapy score over other techniques in treatment of prostate adenocarcinoma. Basu KS; Bahl A; Subramani V; Sharma DN; Rath GK; Julka PK J Cancer Res Ther; 2009; 5(2):78-84. PubMed ID: 19542662 [TBL] [Abstract][Full Text] [Related]
16. Tumor control probability (TCP) and normal tissue complication probability (NTCP) in head and neck cancer. Grégoire V Rays; 2005; 30(2):105-8. PubMed ID: 16294902 [TBL] [Abstract][Full Text] [Related]
17. TCP and NTCP in preclinical and clinical research in Europe. Baumann M; Petersen C; Krause M Rays; 2005; 30(2):121-6. PubMed ID: 16294904 [TBL] [Abstract][Full Text] [Related]
18. Optimization of tumour control probability in hypoxic tumours by radiation dose redistribution: a modelling study. Søvik A; Malinen E; Bruland ØS; Bentzen SM; Olsen DR Phys Med Biol; 2007 Jan; 52(2):499-513. PubMed ID: 17202629 [TBL] [Abstract][Full Text] [Related]
19. Comparison of traditional and simultaneous IMRT boost technique basing on therapeutic gain calculation. Slosarek K; Zajusz A; Szlag M Med Dosim; 2008; 33(4):299-302. PubMed ID: 18973858 [TBL] [Abstract][Full Text] [Related]
20. Clinical heterogeneity and tumor control probability. Eisbruch A Acta Oncol; 2010 Nov; 49(8):1385-7. PubMed ID: 20500028 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]